HOME › DRUGS › BIMATOPROST
ACTIVE SUBSTANCE / INN

BIMATOPROST

Brand name(s): BIMATOPROST, DURYSTA, Durysta, LATISSE, Lumigan, LUMIGAN, ZOLYMBUS
FDA LISTED
EMA LISTED
DISCONTINUED
PRESCRIPTION
APPLICATION WITHDRAWN
NDA211911
NDA022369
ACTIVE SUBSTANCE
Bimatoprost
REGULATORS
FDA · EMA
SPONSORS / MAH
ABBVIE, MICRO LABS LTD INDIA, THEA PHARMA
TOTAL APPLICATIONS
10
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
LUMIGANNDA022184ABBVIEPrescription
BIMATOPROSTANDA203051HIKMADiscontinued
BIMATOPROSTANDA090449APOTEXPrescription
LATISSENDA022369ABBVIEPrescription
BIMATOPROSTANDA204638MICRO LABS LTD INDIANone (Tentative Approval)
DURYSTANDA211911ABBVIEPrescription
ZOLYMBUSNDA217307THEA PHARMAPrescription
LUMIGANNDA021275ABBVIEDiscontinued
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
DurystaAbbVie Deutschland GmbH & Co. KGApplication withdrawnGlaucoma, Open-Angle;Ocular Hypertension
LumiganAbbVie Deutschland GmbH & Co. KGAuthorised08/03/2002Glaucoma, Open-Angle;Ocular Hypertension

FULL INTELLIGENCE ON BIMATOPROST

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →